about
Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of ThroWhich patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Practical management of myelofibrosis with ruxolitinib.
@ast
Practical management of myelofibrosis with ruxolitinib.
@en
type
label
Practical management of myelofibrosis with ruxolitinib.
@ast
Practical management of myelofibrosis with ruxolitinib.
@en
prefLabel
Practical management of myelofibrosis with ruxolitinib.
@ast
Practical management of myelofibrosis with ruxolitinib.
@en
P2093
P2860
P50
P356
P1476
Practical management of myelofibrosis with ruxolitinib
@en
P2093
P2860
P304
P356
10.1111/IMJ.12921
P577
2015-12-01T00:00:00Z